Skip to main
MRNA
MRNA logo

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 9%
Buy 9%
Hold 55%
Sell 27%
Strong Sell 0%

Bulls say

Moderna has projected product sales of $1.73 billion in 2025, which are expected to grow to $2.15 billion in 2026, indicating a solid revenue growth trajectory. The company's recent $1.5 billion debt deal enhances its balance sheet flexibility, positioning it well to navigate uncertainties while capitalizing on future opportunities, alongside improvements in manufacturing efficiency that may increase gross margins by 10% over the next three years. Additionally, positive clinical trial results in diverse therapeutic areas, particularly in oncology, and the potential for continued advancements in its mRNA pipeline contribute to a favorable outlook for Moderna's stock performance.

Bears say

Moderna's stock outlook is negatively impacted by significant declines in revenue from COVID vaccine sales, which are projected to decrease from $18 billion in 2022 to $6.7 billion in 2023, with further reductions anticipated for 2025 due to waning vaccination rates. Additionally, competitive pressures from established RSV vaccines such as Arexvy and Abrysvo hinder the potential commercial success of their mRESVIA program, while the overall progress of their clinical pipeline remains slow in areas outside of respiratory vaccines. Furthermore, the ongoing uncertainty around EU sales negotiations has led to expectations of low sales figures for both 2024 and 2025, contributing to a downward revision of the company's enterprise value from $22.12 billion to $21.53 billion.

Moderna (MRNA) has been analyzed by 11 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 9% recommend Buy, 55% suggest Holding, 27% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 11 analysts, Moderna (MRNA) has a Hold consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.